Walleye Capital LLC reduced its stake in shares of Waldencast plc (NASDAQ:WALD – Get Rating) by 29.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,079 shares of the company’s stock after selling 4,975 shares during the quarter. Walleye Capital LLC owned approximately 0.12% of Waldencast worth $119,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. UBS Group AG grew its position in shares of Waldencast by 295.8% in the 1st quarter. UBS Group AG now owns 3,297 shares of the company’s stock worth $33,000 after buying an additional 2,464 shares during the period. Penserra Capital Management LLC purchased a new stake in Waldencast during the 1st quarter valued at approximately $43,000. Qube Research & Technologies Ltd purchased a new stake in Waldencast during the 1st quarter valued at approximately $279,000. Cantor Fitzgerald L. P. purchased a new stake in Waldencast during the 1st quarter valued at approximately $989,000. Finally, Wolverine Asset Management LLC purchased a new stake in Waldencast during the 2nd quarter valued at approximately $1,812,000.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Waldencast in a report on Wednesday, August 17th. They set a “buy” rating and a $11.00 price objective for the company. DA Davidson increased their price objective on shares of Waldencast from $12.00 to $15.50 and gave the company a “buy” rating in a report on Thursday. Finally, Raymond James began coverage on Waldencast in a research report on Monday, August 22nd. They set an “outperform” rating and a $11.00 target price for the company.
Waldencast Trading Up 0.7 %
Waldencast Company Profile
Waldencast plc, a skincare company, develops, markets, and sells skin health products worldwide. The company offers approximately 200 cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
- Get a free copy of the StockNews.com research report on Waldencast (WALD)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.